Related Experiment Video
Updated: Jan 7, 2026
05:35
Transperineal Prostate Biopsy Using a Cone-shaped Double-hole Method with Dual-plane Probe Guidance
Published on: June 6, 2025
1.2K
Prostate cancer screening
Rodrigo España Navarro1, Daniel Antonio González-Padilla2, José Daniel Subiela3
1Department of Urology, Regional University Hospital, Málaga University, Málaga, Andalucía, Spain.
Asian Journal of Urology
|December 30, 2025
Summary
Prostate cancer screening reduces mortality but carries risks. Shared decision-making and new tools like MRI and biomarkers are key for personalized, precision screening strategies.
Area of Science:
- Oncology
- Urology
- Public Health
Background:
- Prostate cancer (PCa) screening has evolved significantly since the introduction of prostate-specific antigen (PSA) testing.
- Current screening practices face challenges related to efficacy, risks, and overdiagnosis.
Purpose of the Study:
- To review the current status and future directions of prostate cancer screening.
- To evaluate the evidence from randomized controlled trials (RCTs) on PCa screening and treatment.
Main Methods:
- A narrative review of high-quality randomized controlled trials and cohort studies focused on PCa screening and treatment.
- Analysis of population-based trials involving men at average risk for PCa.
Main Results:
- PSA-based screening has shown a reduction in PCa mortality over 10 years but is associated with risks.
- Magnetic Resonance Imaging (MRI) shows promise in targeted diagnostics and screening programs.
- Major society guidelines and risk-adapted strategies are evolving towards precision medicine.
Conclusions:
- PCa screening offers mortality benefits, necessitating shared decision-making between patients and clinicians.
- Emerging technologies like MRI, genetic panels, and biomarkers aim to mitigate screening harms and overdiagnosis.
- Individualized, risk-adapted approaches are crucial for guiding PCa clinical pathways.
